Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 10693.145 | 0.1139 | -0.8452 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 10693.145 | 0.0099 | -0.9912 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 11936.145 | 0.9490 | 0.8798 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 11936.145 | 0.9035 | 0.7736 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 11936.145 | 0.9714 | 0.9324 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 11936.145 | 0.9462 | 0.8733 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 11936.145 | 0.9955 | 0.9894 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 11936.145 | 0.8406 | 0.6285 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 11936.145 | 0.8421 | 0.6319 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 11936.145 | 0.3006 | -0.5176 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 11936.145 | 0.1914 | -0.7174 | 0.8451 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 10872.145 | 0.9805 | 0.9759 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 10872.145 | 0.9928 | 0.9912 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 10872.145 | 0.9932 | 0.9917 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 10872.145 | 0.9640 | 0.9556 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 10872.145 | 1.0140 | 1.0171 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 10872.145 | 0.8614 | 0.8251 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 4 | uM | 10872.145 | 0.3477 | 0.0463 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 20 | uM | 10872.145 | 0.2010 | -0.2522 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 100 | uM | 10872.145 | 0.1681 | -0.3299 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0000853 | uM | 12523.17 | 1.0122 | 1.0271 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.000427 | uM | 12523.17 | 0.9679 | 0.9287 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.00213 | uM | 12523.17 | 1.0457 | 1.1020 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0107 | uM | 12523.17 | 0.9954 | 0.9897 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0533 | uM | 12523.17 | 0.9482 | 0.8852 | 0.8990 |